Ashley Rieger
Acute Care · Asheville, NCNPI 1356776058
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Boehringer Ingelheim at 24.4% of the total. Reporting peaked in 2022 at $1,459 and has fallen 92.7% since, to $106 in 2025. Among acute care clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$878
- GSK$466
- AstraZeneca$411
- Grifols USA, LLC$336
- Sanofi$294
- Mylan Specialty L.p.$208
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,52198%
- Education$762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 41 | $878 |
| GSK | 39 | $466 |
| AstraZeneca | 22 | $411 |
| Grifols USA, LLC | 19 | $336 |
| Sanofi | 15 | $294 |
| Mylan Specialty L.p. | 12 | $208 |
| Regeneron Healthcare Solutions, Inc. | 7 | $189 |
| Genentech USA, Inc. | 7 | $114 |
| United Therapeutics Corporation | 5 | $112 |
| Axsome Therapeutics, Inc. | 4 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $81 |
| Insmed, Inc. | 5 | $78 |
| Sunovion Pharmaceuticals Inc. | 3 | $60 |
| Pharming Healthcare, Inc. | 2 | $53 |
| Pfizer | 3 | $48 |
| CSL Behring | 1 | $39 |
| Nabriva Therapeutics, PLC | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Novartis | 1 | $16 |
How this compares
$3,596 in reported general payments places this provider in the 90th percentile of 312 acute care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 319 | $280,926 |
| OfevNintedanib Esylate | 11 | $144,280 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $71,629 |
| TezspireTezepelumab-Ekko | 14 | $64,086 |
| Spiriva RespimatTiotropium Bromide | 79 | $50,824 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 84 | $50,618 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $35,395 |
| SymbicortBudesonide/Formoterol Fumarate | 137 | $35,393 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $34,709 |
| Spiriva HandihalerTiotropium Bromide | 28 | $15,592 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $11,602 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $10,589 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 345 | $9,603 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 37 | $7,708 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $7,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $466 | $367,354483 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $878 | $253,271187 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $411 | $175,959258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 acute care providers in North Carolina.
Other acute care in Asheville
- Eunbit RuppertAsheville$4K
- Hazel BrewinAsheville$4K
- Benjamin HocuttGreenville$25K
- Matthew KuhnPinehurst$16K
- Robin TruppApex$14K
- Suzanne HartmannRaleigh$12K
- Leigh CasperSalisbury$12K
- Juliana QuagraineCharlotte$11K
- Sarah GroceGreensboro$10K
- Lauren CowellNew Bern$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.